Rinvoq (upadacitinib) / AbbVie - LARVOL DELTA

The Measurement and Management of Fatigue in Atopic Dermatitis: A Scoping Review of Methodologies and Interventions (AAD 2026) - "The anti-IL-4/13 antibody dupilumab has been shown in multiple RCTs and real-world studies to significantly improve sleep disturbance. JAK inhibitors, such as abrocitinib and upadacitinib, have been shown to improve both sleep and, explicitly, fatigue... A robust set of validated tools now exists to measure fatigue and sleep in AD, and these are increasingly being used in clinical trials. The evidence consistently shows that effective treatment of AD with both systemic and supportive therapies leads to significant improvements in sleep and fatigue. The management of fatigue should be considered a key, measurable goal in the treatment of atopic dermatitis."

Review • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Fatigue • Immunology • Sleep Disorder • IL4

Therapeutic Advances in Head and Neck Dermatitis (HND): A Clinical Update (AAD 2026) - " Selective JAK1 inhibitors, including upadacitinib and abrocitinib, achieve rapid and sustained clearance in dupilumab-refractory cases, while topical delgocitinib and roxolitinib have shown benefits without local adverse effects. IL-13 antagonists such as tralokinumab and lebrikizumab provided head-to-neck symptomatic and quality-of-life improvement in patients unresponsive to dupilumab or JAK inhibitors, with a favorable safety profile...Topical agents like ketoconazole and ciclopirox showed good tolerability and clinical improvement in mild cases. Oral itraconazole, while favored for its lipophilic properties and ability to reduce Malassezia-specific IgE, was often followed by relapse upon discontinuation... HND represents a distinct, treatment-resistant AD phenotype requiring strategic multimodal care. Immunomodulators and antifungal therapies, often combined with topical agents, offer promising results, though larger long-term trials are needed to define optimal..."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13

Atopic Dermatitis and Systemic Biologics: Patient Narratives from Social Media Platforms (AAD 2026) - "Search terms included “atopic dermatitis,” “eczema,” “biologic,” “Rinvoq,” “Upadacitinib,” “Dupixent,” “dupilumab,” “Adbry,” and “Tralokinumab.” Eligible posts were patient-created and experience-based. Social media narratives reflect a predominantly positive perception of biologics and JAK inhibitors for AD, with most patients reporting substantial improvement. Given the influence of these platforms, clinicians should remain engaged to support accurate patient education."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Septic Shock

Subgroup Analysis of Efficacy of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata From the UP-AA Phase 3 Program (AAD 2026) - P3 | "At week 24, in adults and adolescents with severe AA, treatment with UPA15 and UPA30 showed higher SALT score≤20 response rates than placebo across all prespecified subgroups and was comparable to the robust efficacy seen in the overall population."

Clinical • P3 data • Alopecia • Immunology

Efficacy and Safety of Upadacitinib in Adolescents and Adults with Severe Alopecia Areata: A Subgroup Analysis of the UP-AA Phase 3 Clinical Program (AAD 2026) - "Safety findings were generally consistent with the known profile for UPA; no deaths were reported in either group. These results suggest that UPA demonstrates high degrees of efficacy for both adolescents and adults with severe AA, with no new safety signals identified in either study."

Clinical • P3 data • Alopecia • Immunology

Real-world outcomes of upadacitinib in severe atopic dermatitis: A retrospective cohort study (AAD 2026) - "Most (18) had also received dupilumab. Upadacitinib was associated with sustained clinical improvement and an acceptable safety profile in real-world patients with difficult-to-treat, severe AD affecting special sites. These findings are consistent with outcomes reported in randomized clinical trials, such as the AD Up study1, and further support the effectiveness and safety of upadacitinib in both settings."

Real-world • Real-world evidence • Retrospective data • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Treatment Persistence and Predictors of Discontinuation in Patients with Atopic Dermatitis Receiving Systemic Therapy: A Retrospective Cohort Study (AAD 2026) - "Systemic therapies included dupilumab, tralokinumab, upadacitinib, methotrexate, cyclosporine, or mycophenolate mofetil. Discontinuation was driven primarily by a number of different factors including inefficacy and adverse events. Dupilumab demonstrated high levels of persistence in this patient population. Further real-world studies with larger populations are necessary to further evaluate predictors for discontinuation."

Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Enhanced Pruritus Relief with JAK Inhibitors Over Cytokine Inhibitors in Atopic Dermatitis: A Real-World Cohort Analysis (AAD 2026) - "This retrospective cohort study used the TriNetX global health research network to compare pruritus outcomes in AD patients treated with Janus kinase (JAK) inhibitors (abrocitinib or upadacitinib) versus cytokine inhibitors (dupilumab or tralokinumab). The more targeted mechanisms of cytokine inhibitors may limit pruritus modulation. Given their superior itch relief, JAK inhibitors should be considered for patients with severe pruritus."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13 • IL4

Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an interim analysis of 3-year data from a real-world multicenter retrospective review (AAD 2026) - "Our real-world study shows superior 3-year outcomes than the Rising Up study and the 140-week upadacitinib Measure Up 1, Measure Up 2, and AD Up extension studies. Study limitations include its sample size and retrospective nature."

Real-world • Real-world evidence • Retrospective data • Review • Acne Vulgaris • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Dyslipidemia • Hypertriglyceridemia • Immunology • Venous Thromboembolism

The Impact of Achieving an Optimal Treatment Target With Upadacitinib Treatment on Health-Related Quality of Life in Adults With Moderate-to-Severe Atopic Dermatitis: Results From the Randomized, Blinded, Treat-to-Target, Phase 3b/4 Flex Up Study (AAD 2026) - "Achievement of EASI90 as well as MDA at week 24 with upadacitinib showed a positive impact on patient outcomes including itch, HRQoL, and sleep, over patients who did not achieve it."

Clinical • HEOR • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Dupilumab versus Upadacitinib in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis (AAD 2026) - "Dupilumab showed higher efficacy across EASI thresholds with broadly comparable safety. Supporting both agents as valid options for moderate-to-severe AD; treatment choice should be guided by clinical context and patient preferences."

Retrospective data • Review • Acne Vulgaris • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Herpes Zoster • Immunology • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Varicella Zoster

BIMEKIZUMAB FOR REFRACTORY HIDRADENITIS SUPPURATIVA AND ASSOCIATED INFLAMMATORY ARTHROPATHIES (AAD 2026) - "We describe a case series of four patients with longstanding HS and IA refractory to multiple systemic agents, including TNF-α inhibitors, IL-17A inhibitors, IL-12/23 inhibitors, methotrexate, and upadacitinib, alone or in combination. Consolidating therapy into a single targeted agent may reduce the need for combination regimens, improve adherence, and minimize treatment-related toxicity. These observations suggest that bimekizumab may represent a promising therapeutic strategy for patients with HS and IA refractory to conventional biologics and immunosuppressants"

Ankylosing Spondylitis • Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL12A • IL17A

Upadacitinib for Steroid-Refractory Immune-Related Cutaneous Adverse Events: A Case Series of Four Patients (AAD 2026) - "All were refractory to topical/systemic steroids, dupilumab, and apremilast. Upadacitinib demonstrated preliminary efficacy and tolerability in patients with steroid refractory irCAEs without evidence of compromised cancer control in this small case series. Larger prospective studies are warranted to define safety, durability of response, and long-term oncologic outcomes."

Adverse events • Clinical • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer

Conjunctivitis Risk with Dupilumab versus Upadacitinib in Atopic Dermatitis: A Propensity- Matched Cohort Study (AAD 2026) - "UPA may confer a protective effect against conjunctivitis relative to DUPI and may be considered for patients with DUPI-associated conjunctivitis."

Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13 • IL17A • IL4 • JAK1

Reassessing Long-Term Safety and Efficacy of Topical and Systemic Therapies in Atopic Dermatitis: An Updated Comparative Review (AAD 2026) - "Topical agents such as high-potency corticosteroids, phosphodiesterase-4 inhibitors, tacrolimus, ruxolitinib, mucopolysaccharide polysulfate cream, and tapinarof cream were found to be effective in improving skin lesions and pruritus in mild-to-moderate AD...Biologics such as dupilumab, lebrikizumab, tralokinumab, and nemolizumab, as well as JAK inhibitors including abrocitinib and upadacitinib, consistently improved EASI scores and overall disease severity. Despite these advances, the limited number of robust comparative studies and standardized criteria for transitioning between treatment classes continues to limit evidence-based decision-making. In the absence of large-scale clinical trials, network meta-analyses and expert consensus panels could be utilized to clarify long-term safety, refine sequencing strategies, and enhance the generalizability of treatment recommendations."

Clinical • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus

Safety of Janus kinase inhibitors for treatment of alopecia areata (AAD 2026) - "Among the remaining 118 patients, 78 (66.1%), 66 (55.9%), 34 (28.8%), 11 (9.3%), and 4 (3.4%) were treated with baricitinib, tofacitinib, ritlecitinib, upadacitinib, and ruxolitinib, respectively. These results show a low incidence of serious AEs, suggesting that JAK inhibitors are well tolerated for the treatment of AA in real-world settings. Further investigations are needed to establish the long-term safety profiles of JAK inhibitors for the treatment of AA."

Clinical • Acne Vulgaris • Alopecia • Cardiovascular • Genito-urinary Cancer • Herpes Simplex • Herpes Zoster • Immunology • Infectious Disease • Pneumonia • Renal Cell Carcinoma • Respiratory Diseases • Solid Tumor • Varicella Zoster

Long-Term 6-Year Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis Across Ages: Results From Three Phase 3 Studies (AAD 2026) - "HZ rates were relatively low in the global adolescent population, with no cases reported in the US adolescent cohort. These findings support the use of UPA across all approved ages in moderate-to-severe AD, with UPA15 remaining the dose of choice in patients ≥65 years to optimize safety."

Clinical • P3 data • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Herpes Zoster • Immunology • Varicella Zoster

Long-Term Maintenance of Stringent Patient-Reported Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Measure Up 1 and 2 Phase 3 Studies (AAD 2026) - "Most patients treated with once-daily upadacitinib 15 mg or 30 mg who achieved a stringent PRO response at week 16 maintained their response through week 140, demonstrating the long-term sustained efficacy of upadacitinib in the treatment of moderate-to-severe AD."

Clinical • P3 data • Patient reported outcomes • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Immunology • Pruritus • Sleep Disorder

Clinical Characteristics of JAK Inhibitor-Associated Acne: A Retrospective Review (AAD 2026) - " We retrospectively reviewed charts of patients at Mount Sinai Dermatology prescribed oral JAK inhibitors (abrocitinib, upadacitinib, tofacitinib, ritlecitinib, or baricitinib) with a documented diagnosis of acne...The most frequently used acne treatments were topical tretinoin (n=20), clindamycin (n=18), and oral doxycycline (n=18)... As JAK inhibitor prescriptions rise, acne is an increasingly observed dermatologic adverse event. Defining risk profiles and timing may enhance patient counseling, clinical monitoring, and therapeutic decision-making."

Retrospective data • Review • Acne Vulgaris • Immunology

Lebrikizumab for Refractory Atopic Dermatitis (AAD 2026) - "All had failed multiple prior systemic therapies, including dupilumab, tralokinumab, upadacitinib, and cyclosporine. Lebrikizumab provided clinically meaningful improvement and favorable tolerability in refractory AD patients unresponsive to multiple systemic therapies. Larger prospective studies are warranted to confirm durability, optimize dosing, and identify predictors of treatment success"

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

Comparative Efficacy and Safety of Novel Biologics and Small-Molecule Therapies for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis (AAD 2026) - "Background Current FDA-approved systemic therapies for moderate-to-severe hidradenitis suppurativa (HS) include TNF-α inhibitors (adalimumab) and IL-17 inhibitors (bimekizumab, secukinumab) (1). Conclusions This NMA identifies JAK1 (porvocitinib, brepocitinib, and upadacitinib) and C5a (vilobelimab) inhibitors as promising investigational treatments for moderate-to-severe HS, representing potential future treatment alternatives for patients refractory to or intolerant of current therapies. However, the small-to-moderate sample sizes and short-term follow-up of such studies highlight the need for future larger, longer-term trials."

Retrospective data • Review • Dermatology • Hidradenitis Suppurativa • Immunology • IL17A • IL23A • JAK1

Evolving Real-World Treatment Patterns and Unmet Needs in Atopic Dermatitis in the United States: Insights from a 2025 Patient Chart Audit and Market Landscaping Study (AAD 2026) - "Lebrikizumab and nemolizumab also sourced patients from tralokinumab, while upadacitinib remained constant at 10% of first-line new start patients. Although dupilumab leads first-line use, rapid uptake of lebrikizumab, nemolizumab, and upadacitinib reflects an evolving landscape. Continued under-treatment, inadequate itch control, and limited sustained response highlight opportunities for innovation to optimize outcomes in AD."

Clinical • HEOR • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Impact of Optimal vs Moderate Skin and Itch Treatment Targets on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: Insights from Measure Up 1 and 2 Phase 3 Studies (AAD 2026) - "This analysis examined the impact of achieving optimal versus moderate skin + itch treatment targets among adults/adolescents with moderate-to-severe AD from two upadacitinib phase 3 studies (Measure Up 1 and 2)... These findings highlight the significance of achieving the optimal target (EASI90 + WP-NRS 0/1) versus moderate target (EASI75 + ∆WP-NRS≥4) to comprehensively minimize patient-reported burden of disease."

Clinical • P3 data • Patient reported outcomes • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis (AAD 2026) - "Upadacitinib demonstrates superior efficacy compared with dupilumab in adults with moderate-to-severe AD, achieving higher rates of EASI 100 with fewer ocular and cutaneous adverse events. These results support upadacitinib as a highly effective alternative to dupilumab."

Retrospective data • Review • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • Respiratory Diseases

Efficacy and Safety of Upadacitinib in Adolescents and Adults for Treatment of Non-Segmental Vitiligo: Results of Two Phase 3 Studies (Viti-Up) (AAD 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Dermatology • Immunology • Vitiligo